Press Release |
|
|
10-12 |
REVIEWS |
|
S.A. Volchenkov, L.V. Filatova, S.V. Lyubimov, I.S. Zyuzgin, S.S. Elkhova, A.A. Zverkova, I.V. Ishmatova, T.Yu. Semiglazova
Modern aspects of nutritional support during hematopoietic stem cell transplantation: review, experience of the N.N. Petrov National Medical Research Center of Oncology
|
14-22 |
|
S.S. Elkhova, L.V. Filatova, I.S. Zyuzgin, S.A. Volchenkov, A.K. Kovyazin, M.S. Motalkina, Yu.A. Chudinovskikh, T.Yu. Semiglazova
Approaches to the mobilization of hematopoietic stem cells: a literature review
|
23-28 |
|
A.I. Tseluiko, V.F. Semiglazov, A.G. Kudaibergenova, A.S. Artemyeva, R.M. Paltuev, R.V. Donskikh, R.S. Pesotsky, P.V. Krivorotko
Clinical immunology of breast cancer
|
29-36 |
|
Sh.R. Abdulaeva, T.Yu. Semiglazova, A.S. Artemyeva, A.G. Kudaibergenova, S.M. Sharashenidze, A.I. Tseluyko, R.M. Paltuev, V.V. Semiglazov, P.V. Krivorotko, V.F. Semiglazov
Predictive and prognostic role of tumor-infiltrating lymphocytes (TILs) in early triple-negative breast cancer
|
37-42 |
|
|
R.S. Pesotsky, V.F. Semiglazov, A.I. Tseluyko, M.D. Sokolova, V.V. Mortada, T.T. Tabagua, P.V. Krivorotko
Treatment of HER2-positive early (minimal) breast cancer
|
43-48 |
|
He Mingze, Zeng Zitong
Modern approaches to the treatment of muscle-invasive bladder cancer
|
49-52 |
ORIGINAL ARTICLES |
|
S.A. Protsenko, G.M. Teletaeva, D.Kh. Latipova, A.I. Semenova, A.V. Novik, Yu.I. Komarov, Sh.A. Dzhalilova, A.Yu. Malygin, E.A. Degtiareva
The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience
|
53-56 |
|
A.V. Andreeva, M.B. Antsiferov
Evaluation of the effectiveness of combination therapy with somatostatin analogues and D2-dopamine receptor agonists in the treatment of persistent or recurrent course of Cushing’s disease
|
57-65 |
|
O.D. Guryeva, M.I. Savelyeva, T.T. Valiev
Influence of pharmacogenetic parameters on clinical variants of methotrexate toxicity in acute lymphoblastic leukemia in children
|
66-70 |
|
I.V. Poddubnaya, N.A. Ognerubov, T.S. Antipova
Thymus hyperplasia after lymphoma drug therapy: the role of PET/CT
|
71-77 |
|
N.P. Belyak, R.V. Orlova, S.I. Kutukova, Yu.V. Pelipas, A.V. Androsova, N.V. Zhukova
Pathological regression as an indicator of the effectiveness of perioperative FLOT/FOLFOX in patients with resectable gastric cancer
|
78-82 |
|
A.V. Androsova, R.V. Orlova, A.K. Ivanova, N.P. Belyak, S.I. Kutukova, A.A. Varankina
The role of some factors of systemic inflammation in the course of gastrointestinal neuroendocrine tumors
|
83-88 |
|
|
I.B. Zhurtova, L.V. Elgarova, A.M. Gubachikova
Immune-mediated endocrine adverse events during treatment with immune checkpoint inhibitors: a clinical case of nivolumab-induced thyroiditis
|
90-94 |
|
Yu.I. Khruleva, I.I. Amergulov, N.V. Likhodey, A.S. Dzyuba, Yu.P. Sych, M.G. Pavlova
Multiple thyroid carcinoma and other long-term endocrine consequences of chemoradiotherapy for medulloblastoma: a clinical case
|
95-99 |
Русский
